ArticleCell communication and signaling : CCS2016

Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.

Sebastian Halbach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.